Edition:
India

Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

57.75USD
20 Sep 2019
Change (% chg)

$-0.71 (-1.21%)
Prev Close
$58.46
Open
$58.47
Day's High
$58.78
Day's Low
$57.75
Volume
30,724
Avg. Vol
17,893
52-wk High
$73.31
52-wk Low
$52.59

Latest Key Developments (Source: Significant Developments)

Biospecifics Technologies Q2 Earnings Per Share $0.87
Saturday, 10 Aug 2019 

Aug 9 (Reuters) - Biospecifics Technologies Corp ::. REPORTS SECOND QUARTER 2019 FINANCIAL AND OPERATING RESULTS.Q2 EARNINGS PER SHARE $0.87.Q2 REVENUE $8.9 MILLION VERSUS $7.9 MILLION.BIOSPECIFICS TECHNOLOGIES - AS OF JUNE 30, 2019, HAD CASH AND CASH EQUIVALENTS & INVESTMENTS OF $93.5 MILLION, VERSUS $82.0 MILLION AS OF DEC 31, 2018.  Full Article

Biospecifics Technologies Corp Reports Q4 Earnings Per Share $0.84
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Biospecifics Technologies Corp ::. REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.84.Q4 REVENUE ROSE 48 PERCENT TO $9.9 MILLION.BIOSPECIFICS TECHNOLOGIES - AS OF DEC 31, 2018, HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $82.0 MILLION, COMPARED TO $65.1 MILLION AS OF DEC 31, 2017.  Full Article

Biospecifics Technologies Corp Announces Passing Of President Thomas Wegman
Monday, 18 Mar 2019 

March 18 (Reuters) - Biospecifics Technologies Corp ::BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES PASSING OF PRESIDENT THOMAS L. WEGMAN.BIOSPECIFICS TECHNOLOGIES CORP - WILL CONTINUE TO BE ACTIVELY MANAGED BY ITS CURRENT EMPLOYEES AND BOARD OF DIRECTORS.BIOSPECIFICS TECHNOLOGIES CORP - SUCCESSION PLANNING IS UNDERWAY AND NEW MANAGEMENT POSITIONS WILL BE ANNOUNCED.  Full Article

BioSpecifics Technologies Reports Q3 Earnings Per Share $0.69
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Biospecifics Technologies Corp ::BIOSPECIFICS TECHNOLOGIES CORP. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.69.Q3 REVENUE $8.2 MILLION VERSUS $6.5 MILLION.  Full Article

BioSpecifics Technologies Announces Positive Topline Results From Phase 1 Study Of CCH
Thursday, 1 Nov 2018 

Oct 31 (Reuters) - BioSpecifics Technologies Corp ::BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 1 STUDY OF CCH FOR THE TREATMENT OF UTERINE FIBROIDS.BIOSPECIFICS TECHNOLOGIES - CCH PHASE 1 STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY WITH NO OBSERVED CLINICALLY SIGNIFICANT ADVERSE REACTIONS.BIOSPECIFICS TECHNOLOGIES CORP - FAVORABLE SAFETY AND TOLERABILITY CONSISTENT WITH CCH CLINICAL TRIALS TO DATE.  Full Article

Biospecifics Technologies Reports Q1 Earnings Per Share $0.54
Wednesday, 9 May 2018 

May 9 (Reuters) - Biospecifics Technologies Corp ::BIOSPECIFICS TECHNOLOGIES CORP. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 EARNINGS PER SHARE $0.54.Q1 REVENUE $7.1 MILLION VERSUS $7.7 MILLION.BIOSPECIFICS - AS OF MARCH 31, 2018, CO HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $64.2 MILLION, COMPARED TO $65.1 MILLION AS OF DEC 31, 2017.BIOSPECIFICS - CO'S CASH, CASH EQUIVALENTS WERE SLIGHTLY LOWER DUE TO THE TIMING OF ENDO'S PAYMENT OF ITS QTRLY XIAFLEX ROYALTIES.  Full Article

Biospecifics Technologies Q4 Earnings Per Share $0.36
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Biospecifics Technologies Corp ::. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.36.‍TOTAL REVENUE FOR Q4 ENDED DECEMBER 31, 2017 WAS $6.7 MILLION, COMPARED TO $6.6 MILLION FOR SAME PERIOD IN 2016​.  Full Article

Biospecifics Technologies reports Q3 eps of $0.37
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Biospecifics Technologies Corp ::Biospecifics Technologies Corp reports Q3 2017 financial results.Q3 revenue $6.5 million versus $6.9 million.Q3 earnings per share $0.37.As of september 30, 2017, co had cash & cash equivalents & investments of $61.3 million.  Full Article